Avalon GloboCare (NASDAQ:ALBT) Shares Up 1.4% – Here’s What Happened

Shares of Avalon GloboCare Corp. (NASDAQ:ALBT) shot up 1.4% on Friday . The company traded as high as $0.37 and last traded at $0.3571. 116,661 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 274,666 shares. The stock had previously closed at $0.3520.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Avalon GloboCare in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Avalon GloboCare Stock Performance

The company has a market cap of $4.30 million, a P/E ratio of -0.10 and a beta of -0.06. The company has a fifty day moving average price of $0.42 and a two-hundred day moving average price of $0.82.

Avalon GloboCare (NASDAQ:ALBT) last announced its quarterly earnings data on Monday, March 30th. The company reported $0.46 earnings per share for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.